
Tianhong (Tina) Li, MD, PhD, from the UC Davis Comprehensive Cancer Center, discusses results from the LUX-Lung 3 trial that examined afatinib as a first-line treatment for patients with EGFR-positive advanced lung adenocarcinoma.

Your AI-Trained Oncology Knowledge Connection!


Tianhong (Tina) Li, MD, PhD, from the UC Davis Comprehensive Cancer Center, discusses results from the LUX-Lung 3 trial that examined afatinib as a first-line treatment for patients with EGFR-positive advanced lung adenocarcinoma.

Dr. Tianhong Li from University of California Davis Cancer Center Describes the Future of Lung Cancer Therapy

Dr. Tianhong Li from UC Davis Cancer Center Discusses the EML4-ALK Fusion Gene

Dr. Tianhong Li from UC Davis Cancer Center Discusses the PROFILE Crizotinib Clinical Trials

Dr. Tianhong (Tina) Li from UC Davic Cancer Center Discusses ALK Gene Mutation Tests

Published: September 1st 2011 | Updated:

Published: September 9th 2011 | Updated:

Published: September 19th 2011 | Updated:

Published: January 17th 2013 | Updated:

Published: August 29th 2011 | Updated: